CN101426766B - 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 - Google Patents

用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 Download PDF

Info

Publication number
CN101426766B
CN101426766B CN200780014073.4A CN200780014073A CN101426766B CN 101426766 B CN101426766 B CN 101426766B CN 200780014073 A CN200780014073 A CN 200780014073A CN 101426766 B CN101426766 B CN 101426766B
Authority
CN
China
Prior art keywords
alkyl
hydrogen
unsubstituted
fluoro
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780014073.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101426766A (zh
Inventor
A·古托普鲁斯
B·C·小艾斯丘
X·陈
S·卡拉
H·余
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Merck Serono SA filed Critical Laboratoires Serono SA
Priority to CN201210488042.5A priority Critical patent/CN103121996B/zh
Publication of CN101426766A publication Critical patent/CN101426766A/zh
Application granted granted Critical
Publication of CN101426766B publication Critical patent/CN101426766B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200780014073.4A 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 Expired - Fee Related CN101426766B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210488042.5A CN103121996B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79307306P 2006-04-19 2006-04-19
US60/793,073 2006-04-19
PCT/US2007/009456 WO2007123936A1 (en) 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210488042.5A Division CN103121996B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Publications (2)

Publication Number Publication Date
CN101426766A CN101426766A (zh) 2009-05-06
CN101426766B true CN101426766B (zh) 2014-03-26

Family

ID=38357968

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780014073.4A Expired - Fee Related CN101426766B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
CN201210488042.5A Expired - Fee Related CN103121996B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210488042.5A Expired - Fee Related CN103121996B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Country Status (14)

Country Link
US (1) US8076486B2 (enExample)
EP (1) EP2013180A1 (enExample)
JP (1) JP5525812B2 (enExample)
KR (1) KR20090005195A (enExample)
CN (2) CN101426766B (enExample)
AR (1) AR060807A1 (enExample)
AU (1) AU2007240860A1 (enExample)
BR (1) BRPI0711625A2 (enExample)
CA (1) CA2644425A1 (enExample)
EA (1) EA200802050A1 (enExample)
IL (1) IL194546A0 (enExample)
MX (1) MX2008013308A (enExample)
WO (1) WO2007123936A1 (enExample)
ZA (1) ZA200807263B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EP2231636B1 (en) * 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
KR20170125931A (ko) * 2015-03-10 2017-11-15 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
JP7245229B2 (ja) 2017-08-21 2023-03-23 ビバーチェ セラピューティクス，インク． ベンゾスルホニル化合物
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
BR112020011162A2 (pt) * 2017-12-07 2020-11-17 Amplyx Pharmaceuticals, Inc. agentes antifúngicos derivados de piridina substituída por heterociclo
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3793551A4 (en) 2018-05-16 2022-01-26 Vivace Therapeutics, Inc. OXADIAZOLE COMPOUNDS
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. HETEROARYL COMPOUNDS
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
WO2025054260A1 (en) * 2023-09-07 2025-03-13 Kinnate Biopharma Inc. Inhibitors of mek kinase
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144215A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
GB2373245A (en) * 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
CA2498281A1 (en) * 2002-09-10 2004-03-25 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents

Also Published As

Publication number Publication date
EP2013180A1 (en) 2009-01-14
MX2008013308A (es) 2008-10-27
ZA200807263B (en) 2009-11-25
US20070287737A1 (en) 2007-12-13
CN103121996B (zh) 2015-10-21
US8076486B2 (en) 2011-12-13
AR060807A1 (es) 2008-07-16
WO2007123936A1 (en) 2007-11-01
JP2009534386A (ja) 2009-09-24
CA2644425A1 (en) 2007-11-01
IL194546A0 (en) 2009-08-03
JP5525812B2 (ja) 2014-06-18
AU2007240860A1 (en) 2007-11-01
HK1127354A1 (en) 2009-09-25
EA200802050A1 (ru) 2009-04-28
KR20090005195A (ko) 2009-01-12
CN103121996A (zh) 2013-05-29
CN101426766A (zh) 2009-05-06
BRPI0711625A2 (pt) 2011-12-06

Similar Documents

Publication Publication Date Title
CN101426766B (zh) 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
CN101868459B (zh) 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物
CN102365277B (zh) Jun n-末端激酶抑制剂
CN101029022B (zh) 含氮芳环衍生物的制备方法
CN100360507C (zh) 用取代杂环脲抑制raf激酶
CN102892759B (zh) 具有犬尿氨酸产生抑制作用的含氮杂环化合物
CN102482218B (zh) 作为蛋白激酶调节剂的吡啶和吡嗪衍生物
CN103508961B (zh) 抗肿瘤药物
HK1216887A1 (zh) 布鲁顿酪氨酸激酶的抑制剂
CN107857755A (zh) 作为trka激酶抑制剂的n‑吡咯烷基、n`‑吡唑基‑脲、硫脲、胍和氰基胍化合物
CN109890822A (zh) 细胞代谢过程的抑制剂
CN105555785B (zh) 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物
CN103261167A (zh) 取代的6，6-稠合含氮杂环化合物及其用途
CN103249732A (zh) 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii
AU2003242591A1 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CN103702990A (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN109608449A (zh) 作为iii型受体酪氨酸激酶抑制剂的化合物
CN102971291B (zh) 新型酰胺衍生物及其作为药物的用途
HK1213544A1 (zh) 新型二环苯基-吡啶/吡嗪用於治疗癌症
TW201623239A (zh) 新穎２－胺基－吡啶及２－胺基－嘧啶衍生物及其醫藥用途
WO2021136354A1 (zh) 联苯类衍生物抑制剂、其制备方法和应用
TW200524903A (en) Quinazoline derivatives
WO2018133826A1 (zh) 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
CN104125947A (zh) 杂环脲化合物
WO2023202623A1 (zh) Polq抑制剂化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1127354

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: MERCK SERONO CO., LTD.

Free format text: FORMER OWNER: SERONO LABORATORIES LTD.

Effective date: 20100324

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100324

Address after: Swiss Coyne Hince

Applicant after: Merck Serono S.A.

Address before: Swiss Coyne Hince

Applicant before: LABORATOIRES SERONO S.A.

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1127354

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140326